Malignant neoplasm of sigmoid colon
ICD-10 C18.7 is a billable code used to indicate a diagnosis of malignant neoplasm of sigmoid colon.
C18.7 refers to a malignant neoplasm located in the sigmoid colon, which is the S-shaped section of the large intestine that connects the descending colon to the rectum. Colorectal cancer, including cancers of the sigmoid colon, is a significant health concern and is often diagnosed through screening methods such as colonoscopy, fecal occult blood tests, and imaging studies. The staging of sigmoid colon cancer is crucial for determining the appropriate treatment plan and prognosis, typically classified using the TNM system (Tumor, Node, Metastasis). This cancer can exhibit microsatellite instability (MSI), a condition that may influence treatment options and is often tested in patients with colorectal cancer. Surgical approaches for managing malignant neoplasms of the sigmoid colon include resection procedures such as sigmoid colectomy, which may be performed laparoscopically or through open surgery, depending on the tumor's size and location. Adjuvant therapies, including chemotherapy and radiation, may also be indicated based on the cancer's stage and characteristics.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Patients presenting with rectal bleeding, changes in bowel habits, or abdominal pain.
Ensure accurate staging and documentation of treatment response.
Endoscopy reports, biopsy results, and follow-up care notes are essential.
Routine screening colonoscopies, surveillance for high-risk patients.
Document findings meticulously to support coding for procedures and diagnoses.
Used when a patient undergoes surgical resection of a malignant sigmoid colon tumor.
Operative report detailing the procedure and findings.
Oncologists and surgeons must ensure accurate staging and pathology correlation.
Microsatellite instability (MSI) is a condition that can occur in colorectal cancers, including those of the sigmoid colon. It indicates a defect in the DNA mismatch repair system and can influence treatment decisions, particularly the use of immunotherapy.
